Literature DB >> 16959545

Inhaled activated protein C attenuates lung injury induced by aerosolized endotoxin in mice.

Anastasia Kotanidou1, Heleni Loutrari, Evangelos Papadomichelakis, Constantinos Glynos, Christina Magkou, Apostolos Armaganidis, Andreas Papapetropoulos, Charis Roussos, Stylianos E Orfanos.   

Abstract

The serine protease activated protein C (APC) possesses prominent anticoagulant and anti-inflammatory actions. In this study, we investigated the effect of inhaled recombinant human (rh) APC in a murine lung injury model. Animals inhaled 10 mg of Pseudomonas lipopolysaccharide (LPS) in 3 mL normal saline (NS); 30 min prior to LPS, mice were pretreated with inhaled rhAPC (4 mg/3 mL NS; APC+LPS group) or NS (LPS group). A control animal group inhaled vehicle (NS) twice. 24 h later, total cells and cell-types, protein content, and the cytokines tumor necrosis factor-alpha, interleukin (IL)-6, macrophage inflammatory protein-1alpha, and mouse keratinocyte-derived chemokine (a homolog of human IL-8) were estimated in bronchoalveolar lavage fluid (BALF). Lung pathology given as total histology score (THS), wet/dry lung weight ratios, and lung vascular cell adhesion molecule (VCAM)-1 expression were additionally assessed. rhAPC inhalation attenuated the aerosolized LPS-induced increases of: total cells, neutrophils and macrophages in BALF, lung tissue VCAM-1 protein levels, and THS. Total protein levels and cytokines in BALF, and wet/dry weight ratios were increased in the LPS group, but rhAPC pretreatment did not significantly alter the LPS-induced responses. In conclusion, in this murine septic model of lung injury, inhaled rhAPC appears to attenuate lung inflammation, without reversing the observed increases in lung permeability and BALF cytokines. This effect may be associated with leukocyte trafficking modifications, related, at least in part, to VCAM-1 reduction.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16959545     DOI: 10.1016/j.vph.2006.06.016

Source DB:  PubMed          Journal:  Vascul Pharmacol        ISSN: 1537-1891            Impact factor:   5.773


  18 in total

Review 1.  Anticoagulant therapy in acute respiratory distress syndrome.

Authors:  Marta Camprubí-Rimblas; Neus Tantinyà; Josep Bringué; Raquel Guillamat-Prats; Antonio Artigas
Journal:  Ann Transl Med       Date:  2018-01

2.  Caveolar uptake and endothelial-protective effects of nanostructured lipid carriers in acid aspiration murine acute lung injury.

Authors:  Matina Kardara; Sophia Hatziantoniou; Aggeliki Sfika; Aliki G Vassiliou; Elena Mourelatou; Christina Muagkou; Apostolos Armaganidis; Charalambos Roussos; Stylianos E Orfanos; Anastasia Kotanidou; Nikolaos A Maniatis
Journal:  Pharm Res       Date:  2013-04-03       Impact factor: 4.200

3.  Inhaled activated protein C protects mice from ventilator-induced lung injury.

Authors:  Nikolaos A Maniatis; Eleftheria Letsiou; Stylianos E Orfanos; Matina Kardara; Ioanna Dimopoulou; Georgios Nakos; Marilena E Lekka; Charalambos Roussos; Apostolos Armaganidis; Anastasia Kotanidou
Journal:  Crit Care       Date:  2010-04-19       Impact factor: 9.097

4.  Inhaled activated protein C: a new therapy for the prevention of ventilator-induced lung injury?

Authors:  Edward Abraham
Journal:  Crit Care       Date:  2010-04-29       Impact factor: 9.097

5.  NAC is associated with additional alleviation of lung injury induced by invasive pulmonary aspergillosis in a neutropenic model.

Authors:  Peng Xu; Jie-Ming Qu; Jin-Fu Xu; Jing Zhang; Hong-Ni Jiang; Hui-Jun Zhang
Journal:  Acta Pharmacol Sin       Date:  2009-07       Impact factor: 6.150

Review 6.  Nebulized anticoagulants in lung injury in critically ill patients-an updated systematic review of preclinical and clinical studies.

Authors:  Jenny Juschten; Pieter R Tuinman; Nicole P Juffermans; Barry Dixon; Marcel Levi; Marcus J Schultz
Journal:  Ann Transl Med       Date:  2017-11

Review 7.  Protective mechanisms of activated protein C in severe inflammatory disorders.

Authors:  Arne P Neyrinck; Kathleen D Liu; James P Howard; Michael A Matthay
Journal:  Br J Pharmacol       Date:  2009-05-14       Impact factor: 8.739

Review 8.  Nebulized anticoagulants for acute lung injury - a systematic review of preclinical and clinical investigations.

Authors:  Pieter R Tuinman; Barry Dixon; Marcel Levi; Nicole P Juffermans; Marcus J Schultz
Journal:  Crit Care       Date:  2012-12-12       Impact factor: 9.097

9.  Activated protein C inhalation: a novel therapeutic strategy for acute lung injury.

Authors:  Lulong Bo; Jinjun Bian; Jinbao Li; Xiaojian Wan; Keming Zhu; Xiaoming Deng
Journal:  Med Sci Monit       Date:  2011-06

10.  Barrier-protective effects of activated protein C in human alveolar epithelial cells.

Authors:  Ferranda Puig; Gemma Fuster; Mélanie Adda; Lluís Blanch; Ramon Farre; Daniel Navajas; Antonio Artigas
Journal:  PLoS One       Date:  2013-02-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.